$ABSI

Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.

Advanced Micro Devices (AMD) filed its first 13F, revealing a $1.31 billion portfolio with six positions. Top holdings include SpaceX, Absci (ABSI), Sanmina (SANM), Nutanix (NTNX), and Quantum Computing (QUBT). AMD's Q2 revenue surged 50.1% YoY to $11.536 billion, with data center revenue doubling. AMD expects Q3 revenue of $13 billion, citing strong AI demand.

Absci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.

Absci Corp (ABSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly

Anthropic is reportedly targeting an IPO in September or early October 2026, according to the Wall Street Journal. In investor meetings, it said it plans to expand healthcare and biology AI use cases. The article highlights potential AI-biotech beneficiaries, citing results and guidance for Absci, Recursion, Schrodinger, Twist Bioscience, and Tempus AI, including Tempus Q2 revenue of $382.49M and raised FY guidance to $1.595 to $1.605B.

Szela Mary T purchased 12,900 shares of Absci Corp (ABSI) at $11.54 ($0.15M total) on 2026-06-30.

Absci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.

Absci Corp (ABSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d139233dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version ABSCI CORPORATION 13,495,277 Shares of Common Stock Underwriting Agreement June 24, 2026 Jefferies LLC J.P. Morgan Securities LLC TD Securities (USA) LLC Guggenheim Securities, LLC As Representatives of the sev

Absci (NASDAQ:ABSI) shares rose 11% on Friday, despite missing quarterly earnings and revenue expectations significantly. The company operates with a negative net margin and analysts forecast a negative EPS for the fiscal year, leading to a consensus "Hold" rating with an average price target of $6.44. Insider ownership is 10.49% (including a recent purchase by Andreas Busch) and institutional ownership is approximately 52%.

Several prominent stocks are projected to open lower in Wednesday's pre-market session. Absci Corp (NASDAQ: ABSI) is down after reporting lower-than-expected quarterly sales, while DigitalOcean Holdings Inc (NYSE: DOCN) declined following a $700 million offering announcement. Other companies experiencing pre-market dips include Intrepid Potash Inc (NYSE: IPI), Pacira Biosciences Inc (NASDAQ: PCRX), Velo3D Inc (NASDAQ: VELO), Sasol Ltd (NYSE: SSL), CF Industries Holdings, Inc. (NYSE: CF), and Venture Global Inc (NASDAQ: VG).